Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overactive Clear all
Completed Phase 4 Interventional Results available

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

NCT02092181
View directory record Official record
Conditions
Parkinsons Disease
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Daniel Burdick, MD
Individual
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 22, 2026, 5:10 AM EDT
Not listed Not applicable Interventional

Painless Laser Therapy for Overactive Bladder

NCT01569061
View directory record Official record
Conditions
Overactive Bladder
Interventions
LCT-1000TM (Manufacturer: LiteCure)
Device
Lead sponsor
Zipper Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

NCT04754737
View directory record Official record
Conditions
Antibiotic Stewardship, Overactive Bladder, Onabotulinumtoxin A, UTI
Interventions
No antibiotic, Prophylactic antibiotic, cystoscopic injection of onabotulinumtoxinA
Other · Procedure
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

NCT00427596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 22, 2026, 5:10 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

NCT07175805
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Urge Urinary Incontinence, Overactive Bladder, Pelvic Organ Prolapse, Weight Loss, Fecal Incontinence, Bariatric Surgery, glp1 Agonist
Interventions
Bariatric Surgery, GLP1 receptor agonist
Procedure · Drug
Lead sponsor
Hartford HealthCare
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Uro-NIRS Clinical Study

NCT00706407
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Fully integrated Uro-NIRS:UDS
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB

NCT02857816
View directory record Official record
Conditions
Overactive Bladder
Interventions
NURO System PTNM Therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
St. Petersburg, Florida • Evanston, Illinois • Cambridge, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Results available

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence

NCT03535857
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Interventions
PTNS
Device
Lead sponsor
Gnankang Sarah Napoe
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Evaluating the Optimal Volume Voided for Passage of a Backfill-Assisted Voiding Trial Following Urogynecologic Surgery

NCT05820139
View directory record Official record
Conditions
Voiding Dysfunction
Interventions
Control Group, Test Group
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

NCT01089751
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

NCT01286454
View directory record Official record
Conditions
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions
fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)

NCT01502956
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
InterStim® device, Botox® injection
Device · Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929
View directory record Official record
Conditions
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TTNS vs PTNS in a County Hospital System.

NCT07353944
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tibial nerve stimulation
Device
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

NCT00444925
View directory record Official record
Conditions
Overactive Bladder
Interventions
fesoterodine fumarate, placebo, tolterodine tartrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Research Study for Patients With Overactive Bladder

NCT00168454
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
botulinum toxin Type A, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

NCT00892450
View directory record Official record
Conditions
Parkinson's Disease, Overactive Bladder
Interventions
Oxybutynin and darifenacin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"

NCT02180048
View directory record Official record
Conditions
Overactive Bladder, Caffeine, Menopause
Interventions
400 mg of caffeine/day (Two 200mg pills/day), 200 mg of caffeine/day (One 200mg pill and one placebo pill), Two placebo pills/day
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
58 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Not applicable Interventional Results available

TENS Used for Pain Management During Office Cystoscopy Botox Injections

NCT04448171
View directory record Official record
Conditions
Overactive Bladder
Interventions
Active TENS, Sham TENS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 22, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Validation of a Real-time Urodynamic Measure of Urinary Urgency

NCT00909428
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Solifenacin Succinate
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 22, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

NCT00712322
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Darifenacin
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
2 Years to 15 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 22, 2026, 5:10 AM EDT